Gliclazide MR among sulfonylureas drugs: primus inter pares

• Alexander S. Ametov
• Prudnikova M.A.

Abstract

Sulfonylureas take a central place in the pharmacotherapy of diabetes mellitus type 2 for many years. The main purpose of this article is to highlight the current scientific data about gliclazide. Gliclazide is sulfonylurea drug with unique properties, which distinguish it from the other drugs this group. Gliclazide has high selectivity, it blocks SUR receptor reversibly and recovers I phase of insulin secretion. Patients taking gliclazide have very low risk of hypoglycemia and weight gain. This drug improves cardiovascular outcomes.

Keywords:diabetes mellitus type 2, sulfonylurea, gliclazide

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)